Drug Profile
Research programme: IgE inhibitors - Interprotein
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Interprotein Corporation
- Class Small molecules
- Mechanism of Action Immunoglobulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Allergy in Japan (PO)
- 31 Dec 2009 Early research in Hypersensitivity in Japan (PO)